Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

NCT04921722 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Kaposiform Hemangioendothelioma
Tufted Angioma
Superficial Vascular Anomalies
Superficial Lymphatic Malformations

Interventions

DRUG: Percutaneous sirolimus
DRUG: Oral sirolimus

Sponsor

Children's Hospital of Fudan University